Free Trial

Nuwellis (NUWE) Competitors

Nuwellis logo
$12.12 -0.88 (-6.77%)
Closing price 04:00 PM Eastern
Extended Trading
$11.98 -0.15 (-1.20%)
As of 07:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

NUWE vs. GCTK, NAOV, BJDX, TTOO, IVF, LGMK, BBLG, AVGR, DYNT, and NAYA

Should you be buying Nuwellis stock or one of its competitors? The main competitors of Nuwellis include GlucoTrack (GCTK), Nanovibronix (NAOV), Bluejay Diagnostics (BJDX), T2 Biosystems (TTOO), INVO Fertility (IVF), LogicMark (LGMK), Bone Biologics (BBLG), Avinger (AVGR), Dynatronics (DYNT), and NAYA Biosciences (NAYA). These companies are all part of the "medical equipment" industry.

Nuwellis vs. Its Competitors

GlucoTrack (NASDAQ:GCTK) and Nuwellis (NASDAQ:NUWE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, profitability, analyst recommendations, valuation, earnings and risk.

Nuwellis has higher revenue and earnings than GlucoTrack. GlucoTrack is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GlucoTrackN/AN/A-$22.60M-$56.60-0.13
Nuwellis$8.74M0.14-$11.16M-$766.39-0.02

10.9% of GlucoTrack shares are owned by institutional investors. Comparatively, 3.1% of Nuwellis shares are owned by institutional investors. 12.9% of GlucoTrack shares are owned by company insiders. Comparatively, 1.6% of Nuwellis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

GlucoTrack has a beta of -0.24, suggesting that its stock price is 124% less volatile than the S&P 500. Comparatively, Nuwellis has a beta of 0.28, suggesting that its stock price is 72% less volatile than the S&P 500.

In the previous week, Nuwellis had 3 more articles in the media than GlucoTrack. MarketBeat recorded 5 mentions for Nuwellis and 2 mentions for GlucoTrack. GlucoTrack's average media sentiment score of 1.35 beat Nuwellis' score of 0.24 indicating that GlucoTrack is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
GlucoTrack
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nuwellis
0 Very Positive mention(s)
0 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Nuwellis has a consensus price target of $714.00, suggesting a potential upside of 5,791.09%. Given Nuwellis' stronger consensus rating and higher probable upside, analysts clearly believe Nuwellis is more favorable than GlucoTrack.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
GlucoTrack
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Nuwellis
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

GlucoTrack has a net margin of 0.00% compared to Nuwellis' net margin of -112.09%. GlucoTrack's return on equity of 0.00% beat Nuwellis' return on equity.

Company Net Margins Return on Equity Return on Assets
GlucoTrackN/A N/A -544.87%
Nuwellis -112.09%-655.31%-141.83%

Summary

Nuwellis beats GlucoTrack on 9 of the 15 factors compared between the two stocks.

Get Nuwellis News Delivered to You Automatically

Sign up to receive the latest news and ratings for NUWE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUWE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NUWE vs. The Competition

MetricNuwellisMED INSTRUMENTS IndustryMedical SectorNASDAQ Exchange
Market Cap$1.35M$6.85B$5.70B$9.51B
Dividend YieldN/A1.27%4.69%4.01%
P/E Ratio-0.0219.2121.1920.14
Price / Sales0.1463.54461.30104.37
Price / CashN/A20.5536.2258.56
Price / Book0.194.758.665.87
Net Income-$11.16M$176.14M$3.25B$258.55M
7 Day Performance-18.11%2.92%4.20%2.23%
1 Month Performance13.12%3.56%10.82%12.76%
1 Year Performance-88.46%7.66%34.70%19.36%

Nuwellis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NUWE
Nuwellis
3.034 of 5 stars
$12.12
-6.8%
$714.00
+5,791.1%
-87.6%$1.35M$8.74M-0.0270
GCTK
GlucoTrack
0.4064 of 5 stars
$5.45
-3.5%
N/A-99.5%$2.61MN/A-0.105
NAOV
Nanovibronix
0.256 of 5 stars
$0.95
+1.1%
N/A-88.9%$2.45M$2.56M-0.0720
BJDX
Bluejay Diagnostics
1.2425 of 5 stars
$1.64
+1.9%
N/A-94.4%$2.45MN/A0.009Positive News
TTOO
T2 Biosystems
2.2718 of 5 stars
$0.11
-0.9%
$5.00
+4,251.6%
-99.4%$2.42M$7.68M0.00180Upcoming Earnings
IVF
INVO Fertility
N/A$0.80
+1.6%
N/A-91.8%$1.73M$6.59M-0.0210News Coverage
Stock Split
Gap Up
LGMK
LogicMark
0.1265 of 5 stars
$0.00
-6.3%
N/A-100.0%$1.73M$9.88M0.0020Gap Down
BBLG
Bone Biologics
0.7296 of 5 stars
$2.90
+0.7%
N/A-73.7%$1.60MN/A0.002Positive News
AVGR
Avinger
N/A$0.47
flat
N/AN/A$1.57M$7.65M-0.0470
DYNT
Dynatronics
N/A$0.09
-7.4%
N/A-63.7%$935K$33.60M-0.11200Gap Down
NAYA
NAYA Biosciences
N/A$0.78
-5.4%
$24.00
+2,993.6%
N/A$517K$6.23M0.0010High Trading Volume

Related Companies and Tools


This page (NASDAQ:NUWE) was last updated on 7/25/2025 by MarketBeat.com Staff
From Our Partners